Condition: Cocaine Use Disorder · Sponsor: The University of Texas Health Science Center, Houston
The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).
This description comes directly from the study's public registry record.
Luba Yammine, PhD · (713) 486-2737 · Luba.Yammine@uth.tmc.edu
Jessica Vincent · (713) 486-2645 · Jessica.N.Vincent@uth.tmc.edu
Always discuss trial participation with your own doctor first.
| The University of Texas Health Science Center at Houston | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227948